Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Theratechnologies ( (TSE:TH) ) has issued an update.
Theratechnologies has announced the availability of EGRIFTA WR™, a new formulation of tesamorelin for injection, approved by the FDA for reducing excess abdominal fat in adults with HIV and lipodystrophy. This new version offers weekly reconstitution and reduced injection volume, aiming to improve patient experience and simplify treatment. The introduction of EGRIFTA WR™ is expected to gradually replace the existing EGRIFTA SV® formulation, with specialty pharmacies already ordering the new product. The transition is supported by the Thera Patient Support program to ensure a smooth changeover for patients.
The most recent analyst rating on (TSE:TH) stock is a Hold with a C$4.50 price target. To see the full list of analyst forecasts on Theratechnologies stock, see the TSE:TH Stock Forecast page.
Spark’s Take on TSE:TH Stock
According to Spark, TipRanks’ AI Analyst, TSE:TH is a Neutral.
Theratechnologies’ overall score is driven by positive corporate events, including a favorable acquisition agreement, which boosts shareholder value. Strong technical indicators also support the stock’s outlook. However, financial performance and valuation challenges, such as negative equity and a lack of profitability, weigh on the score.
To see Spark’s full report on TSE:TH stock, click here.
More about Theratechnologies
Theratechnologies Inc. is a commercial-stage biopharmaceutical company focused on developing and commercializing innovative therapies. The company specializes in products aimed at addressing unmet medical needs, particularly for people living with HIV.
Average Trading Volume: 51,115
Technical Sentiment Signal: Hold
Current Market Cap: C$206.9M
For an in-depth examination of TH stock, go to TipRanks’ Overview page.